Psoriasis is a systemic inflammatory disease associated with increased risk of comorbidities,
such as psoriatic arthritis, Crohn's disease, malignancy, obesity, and cardiovascular …

The past century has been characterized by intensive efforts, within both academia and the
pharmaceutical industry, to introduce new treatments to individuals with rheumatic …

Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with
heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed …

Background Many drugs approved for other indications can control the growth of tumor cells
and limit adverse events (AE). Data sources Literature searches with keywords 'repurposing …

The time and cost of developing new drugs have led many groups to limit their search for
therapeutics to compounds that have previously been approved for human use. Many …

Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence
of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis …

Phosphodiesterase (PDE) 4 is a superfamily of enzymes that catalyze the hydrolysis of cyclic
adenosine 3', 5'-monophosphate (cAMP), an intracellular second messenger and regulator …

Both primary and secondary forms of cicatricial alopecia have been described. The hair
follicles are the specific target of inflammation in primary cicatricial alopecias. Hair follicles …

Agents which increase intracellular cyclic adenosine monophosphate (cAMP) may have an
antagonistic effect on pro-inflammatory molecule production so that inhibitors of the cAMP …

Formidable impediments stand in the way of treatment development for lupus. These include
the unwieldy size of current trials, international competition for scarce patients, complex …